Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 36Myeloid 31Gastrointestinal 7Tumor-Agnostic 6Sarcoma 6Dermatologic 4Lymphoid 3Gynecologic 2CNS 1

Conditions

Melanoma 3Mucosal Lentiginous Melanoma 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × nilotinib × Dermatologic × Clear all
NCT00788775 2018-11-15

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled 14 charts
Dermatologic

Melanoma

NCT01395121 2017-06-08

NICAM

Institute of Cancer Research, United Kingdom

Phase 2 Completed
29 enrolled
Dermatologic

Mucosal Lentiginous Melanoma

NCT01028222 2015-12-30

TEAM

Novartis

Phase 2 Completed
55 enrolled 13 charts
Dermatologic

Melanoma

NCT01168050 2011-02-08

NILOMEL

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡